At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 100 enrolled
Drug / intervention
Liposomal bupivacaine +1 moredrug
Likely dose
Liposomal bupivacaine 1 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma
In Brief
A Phase 2 clinical trial evaluating Liposomal bupivacaine and 0.9% sodium chloride for Blunt Chest Wall Trauma and 2 related conditions. Completed, enrolled 100 participants across 1 site.
Detailed Summary
This is a study of liposomal bupivacaine for pain control in patients with blunt chest wall trauma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlunt Chest Wall Trauma, Rib Fracture, Sternal Fracture
CountriesUnited States
CollaboratorsUnited States Air Force
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartMar 2018
Primary CompletionJan 2021
TodayJul 2026
First PostedApr 25, 2016
Enrollment StartMar 9, 2018
Primary CompletionJan 1, 2021
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 10.2 years ago
Interventions
Liposomal bupivacainedrug
1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
0.9% sodium chloridedrug
1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position